ULTRAGENYX PHARMA PLUNGES 45% PREMARKET AFTER CO'S RARE DISEASE DRUG FAILS TO MEET MAIN GOAL IN LATE-STAGE TRIAL

Reuters · 1d ago

Please log in to view news